Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 2
1999 1
2004 3
2009 1
2012 2
2013 2
2014 1
2015 2
2016 1
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean damario m[au] (85 results)?
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. Ott PA, et al. Among authors: demario m. Cell. 2020 Oct 15;183(2):347-362.e24. doi: 10.1016/j.cell.2020.08.053. Cell. 2020. PMID: 33064988
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. Shapiro GI, et al. Among authors: demario m. Br J Cancer. 2021 Feb;124(4):744-753. doi: 10.1038/s41416-020-01180-1. Epub 2020 Dec 14. Br J Cancer. 2021. PMID: 33311588 Free PMC article.
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD. Lassen UN, et al. Among authors: demario m. Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11. Clin Cancer Res. 2015. PMID: 25388164 Free article. Clinical Trial.
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH. Meulendijks D, et al. Among authors: demario m. Clin Cancer Res. 2016 Feb 15;22(4):858-67. doi: 10.1158/1078-0432.CCR-15-1506. Epub 2015 Oct 7. Clin Cancer Res. 2016. PMID: 26446946 Free article. Clinical Trial.
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, Wang X, Packman K, Rosinski J, Berkofsky-Fessler W, Tang JP, Pant S, Geho D, Vega-Harring S, Demario M, Levitsky H, Simcox M. Yin X, et al. Among authors: demario m. Clin Cancer Res. 2013 Oct 15;19(20):5686-98. doi: 10.1158/1078-0432.CCR-13-0405. Epub 2013 Aug 23. Clin Cancer Res. 2013. PMID: 23974006 Free article.
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.
Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, Rosinski J, McLoughlin P, Ritland S, DeMario M, Tobon K, Reidhaar-Olson JF, Rueger R, Hilton H. Berkofsky-Fessler W, et al. Among authors: demario m. Mol Cancer Ther. 2009 Sep;8(9):2517-25. doi: 10.1158/1535-7163.MCT-09-0083. Epub 2009 Sep 15. Mol Cancer Ther. 2009. PMID: 19755512 Free article. Clinical Trial.
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Lohmann S, Herold A, Bergauer T, Belousov A, Betzl G, Demario M, Dietrich M, Luistro L, Poignée-Heger M, Schostack K, Simcox M, Walch H, Yin X, Zhong H, Weisser M. Lohmann S, et al. Among authors: demario m. Methods. 2013 Jan;59(1):10-9. doi: 10.1016/j.ymeth.2012.07.003. Epub 2012 Jul 14. Methods. 2013. PMID: 22796720 Free article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page